MicrobiologymBioPeer-reviewed
Sorafenib, a clinically approved kinase inhibitor attenuates Streptococcus pneumoniae pathogenesis in vivo by targeting serine/threonine kinase StkP
Joel Abraham, Aswathy C. Sagilkumar, Himani Dhyani…·Karthik Subramanian
This study shows that sorafenib, a cancer drug, targets StkP in Streptococcus pneumoniae, reducing bacterial pathogenesis and mortality in mice.